Ipsen

Ipsen
TypePublic
Euronext Paris: IPN
CAC Mid 60 Component
ISINFR0010259150
IndustryPharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBalard, Paris 15, France
Key peopleMarc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
RevenueIncrease €3.401 billion(2024)
Increase €1.109 billion(2024)
Increase €347million(2024)
Number of employees
5,300
Websitewww.ipsen.com
Footnotes

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005). The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.